Use este identificador para citar o ir al link de este elemento:
http://hdl.handle.net/1843/56584| Tipo: | Artigo de Periódico |
| Título: | Medication persistence for psoriatic arthritis in a Brazilian real-world setting |
| Autor(es): | Michael Ruberson Ribeiro da Silva Jéssica Barreto Ribeiro dos Santos Alessandra Maciel Almeida Alexander Itria Adriana Maria Kakehasi Juliana Alvares Teodoro Francisco de Assis Acurcio |
| Resumen: | Aim: To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional syntheticdisease-modifyingantirheumaticdrugs[csDMARDs])antirheumaticagentsforpsoriaticarthritisand their associated factors. Methods: A historical cohort was developed. Persistence and associated factors wereevaluatedat6and12months.Results:Atotalof161patientswereincluded.Theanti-TNFtreatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4vs35.6%;p<0.05).Fromanti-TNFs,adalimumabandetanerceptpresentedsimilarpersistence,along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence withregardtoanti-TNFagentswerefemalesexanduseofinfliximab.Conclusion:Anti-TNFagentsareimportanttherapeuticalternativesand presentlowerratesofdiscontinuationascomparedwithcsDMARDs. Lay abstract: Conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and anti-TNF agents were included in the Brazilian National Health System in 2009, yet were not previously the target of evaluations in a Brazilian context. Persistence, that is the time between starting and discontinuing the drug, is a proxy of effectiveness and safety for antirheumatic agents. This study evaluated medication persistence and relevant factors associated with it. Patients using infliximab showed a lower medication persistence when compared with adalimumab and etanercept. The medication persistence with anti-TNF agents was higher when compared with csDMARDs. Female sex and infliximab were predictors of medication non-persistence. |
| Asunto: | Agentes anti-reumaticos Medicamentos |
| Idioma: | por |
| País: | Brasil |
| Editor: | Universidade Federal de Minas Gerais |
| Sigla da Institución: | UFMG |
| Departamento: | FAR - DEPARTAMENTO DE FARMÁCIA SOCIAL MED - DEPARTAMENTO DE APARELHO LOCOMOTOR MED - DEPARTAMENTO DE CLÍNICA MÉDICA |
| Tipo de acceso: | Acesso Aberto |
| Identificador DOI: | https://doi.org/10.4155/fsoa-2018-0101 |
| URI: | http://hdl.handle.net/1843/56584 |
| Fecha del documento: | 2019 |
| metadata.dc.url.externa: | https://www.future-science.com/doi/10.4155/fsoa-2018-0101 |
| metadata.dc.relation.ispartof: | Future Science OA |
| Aparece en las colecciones: | Artigo de Periódico |
archivos asociados a este elemento:
| archivo | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| Medication persistence for psoriatic arthritis in a Brazilian real-world setting.pdf | 183.85 kB | Adobe PDF | Visualizar/Abrir |
Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.